Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Summary

This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), node-positive (N+) high risk early breast cancer patients with obesity or overweight, inhibiting the growth and survival of micrometastatic disease and leading to clearance of tumor-informed circulating tumor DNA (ctDNA) and freedom from the development of metastatic disease.

Timeline

Start

2024-11-26

Primary completion

2029-08-31

Completion

2030-12-31

Drugs

Indications